Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genetic predictors of response to ranibizumab in age-related macular degeneration
2008-007319-33Phase 4Completed
- Sponsor
- Leeds Teaching Hospitals NHS Trust
- Start
- Nov 2010
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ranibizumab in exudative macular degeneration, sponsored by Leeds Teaching Hospitals NHS Trust. Primary endpoints: Change in visual acuity at 6 months by genotype and Number of ranibizumab injections over 6 months by genotype. Started Nov 2010; status: completed.
02
Drugs
ranibizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2008-007319-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007319-33.